A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study

BACKGROUND: Malignant glioma is the most common primary malignant brain tumor that displays high vascularity, making vascular endothelial growth factor receptors become promising targets. This study was conducted to evaluate the efficacy and safety of apatinib, a new potent oral small-molecule tyros...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Liang, Lijun, Yang, Tao, Qiao, Yun, Xia, Youyou, Liu, Liang, Li, Chao, Lu, Peizhi, Jiang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728925/
https://www.ncbi.nlm.nih.gov/pubmed/29245310
http://dx.doi.org/10.1097/MD.0000000000009053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728925/
https://www.ncbi.nlm.nih.gov/pubmed/29245310
http://dx.doi.org/10.1097/MD.0000000000009053

Ejemplares similares